A Phase 2 study of a new antibody treatment for Alzheimer’s disease has failed to meet its primary endpoint using an adaptive trial design that was intended to show efficacy at 12 months. Biogen Inc and Eisai Co Ltd said the blinded study will continue until the second half of 2018.
